Arcutis Biotherapeutics, Inc.: Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | WESTLAKE VILLAGE, Calif., Sept. 05, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations... ► Artikel lesen |
Arcutis Biotherapeutics, Inc.: Arcutis Submits Supplemental New Drug Application for ZORYVE (roflumilast) Cream 0.3% to Expand Indication for Treatment of Plaque Psoriasis in Children Ages 2 to 5 | If approved, ZORYVE cream would be the first and only topical PDE4 inhibitor indicated for plaque psoriasis in children as young as 2, offering patients and caregivers an important alternative to... ► Artikel lesen |
Arcutis Biotherapeutics, Inc.: Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | WESTLAKE VILLAGE, Calif., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations... ► Artikel lesen |
Aktien New York: Stabil - Anleger trotz 'Shutdown'-Gefahr gelassen | NEW YORK (dpa-AFX) - Nach dem Rekordlauf der US-Börsen vor einer Woche und darauf folgenden Verlusten hat die US-Technologiebörse Nasdaq am Montag erneut zugelegt. Allerdings bröckelten die Gewinne... ► Artikel lesen |
ROUNDUP/Aktien Europa Schluss: Auf hohem Niveau risikoscheu - Blick geht gen USA | AMSTERDAM/LONDON/PARIS/ZÜRICH (dpa-AFX) - Europas wichtigste Aktienmärkte sind am Montag mehrheitlich nur wenig gestiegen. Etwas deutlicher ging es in der Schweiz nach oben. Angesichts der Unsicherheiten... ► Artikel lesen |
ROUNDUP/Aktien New York: Trotz 'Shutdown'-Gefahr steigt Nasdaq gen Rekordhoch | NEW YORK (dpa-AFX) - Nach dem Rekordlauf der US-Börsen vor einer Woche und darauf folgenden Verlusten hat die US-Technologiebörse Nasdaq am Montag erneut zugelegt. Auch der breit gefasste S&P 500 gewann... ► Artikel lesen |
Immunovant Inc.: Immunovant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients | First-ever potentially disease-modifying therapy for uncontrolled Graves' disease patientsOf 21 patients who entered the six-month off-treatment follow-up period, ~80% (17/21) demonstrated response... ► Artikel lesen |
Immunovant Inc.: Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2025 | Initiated a second potentially registrational study of IMVT-1402 in Graves' disease (GD) and a potentially registrational study of IMVT-1402 in Sjögren's disease (SjD), both in June 2025All other... ► Artikel lesen |
Immunovant Inc.: Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025 | Immunovant's new management team is focused on rapid clinical execution for the six announced indications for IMVT-1402, including a second potentially registrational study in Graves' disease (GD)... ► Artikel lesen |